CO2021012391A2 - Estabilidad api mejorada en capsulas blandas - Google Patents

Estabilidad api mejorada en capsulas blandas

Info

Publication number
CO2021012391A2
CO2021012391A2 CONC2021/0012391A CO2021012391A CO2021012391A2 CO 2021012391 A2 CO2021012391 A2 CO 2021012391A2 CO 2021012391 A CO2021012391 A CO 2021012391A CO 2021012391 A2 CO2021012391 A2 CO 2021012391A2
Authority
CO
Colombia
Prior art keywords
soft capsule
weight
softgels
capsule shell
composition
Prior art date
Application number
CONC2021/0012391A
Other languages
English (en)
Inventor
Douglas Keith Durham
Hitesh S Patel
Original Assignee
Scherer Technologies Llc R P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scherer Technologies Llc R P filed Critical Scherer Technologies Llc R P
Publication of CO2021012391A2 publication Critical patent/CO2021012391A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se suministran cápsulas blandas que tienen estabilidad mejorada de ingredientes farmacéuticos activos y métodos para preparar las mismas. En algunas modalidades, una cápsula blanda comprende una composición de material de relleno y una cubierta de cápsula blanda. En algunas modalidades, la composición de material de relleno de la cápsula blanda comprende uno o más ingredientes farmacéuticos activos (API); 2 a 15% en peso de povidona; 30 a 60% en peso de polietilenglicol; y 0.5 a 5% en peso de propilenglicol, en donde la composición de material de relleno tiene un pH de 3.75 o menos. En algunas modalidades, la cubierta de cápsula blanda está hecha de una composición de cubierta de cápsula blanda que comprende un componente acídico.
CONC2021/0012391A 2019-03-11 2021-09-22 Estabilidad api mejorada en capsulas blandas CO2021012391A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962816621P 2019-03-11 2019-03-11
PCT/US2020/022114 WO2020185904A1 (en) 2019-03-11 2020-03-11 Improved api stability in softgels

Publications (1)

Publication Number Publication Date
CO2021012391A2 true CO2021012391A2 (es) 2021-10-20

Family

ID=70277456

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0012391A CO2021012391A2 (es) 2019-03-11 2021-09-22 Estabilidad api mejorada en capsulas blandas

Country Status (13)

Country Link
US (1) US20220175683A1 (es)
EP (1) EP3937910A1 (es)
JP (1) JP2022526238A (es)
KR (1) KR20210137161A (es)
CN (1) CN113795244A (es)
AR (1) AR118320A1 (es)
AU (1) AU2020235883A1 (es)
BR (1) BR112021017876A2 (es)
CA (1) CA3134031A1 (es)
CO (1) CO2021012391A2 (es)
IL (1) IL286239A (es)
MX (1) MX2021010959A (es)
WO (1) WO2020185904A1 (es)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0717498B2 (ja) * 1989-05-31 1995-03-01 興和株式会社 鎮咳去痰ソフトカプセル剤
US5141961A (en) * 1991-06-27 1992-08-25 Richrdson-Vicks Inc. Process for solubilizing difficulty soluble pharmaceutical actives
AU6276996A (en) * 1995-07-05 1997-02-05 Procter & Gamble Company, The Warming compounds
BR112015018838B1 (pt) * 2013-02-28 2020-12-15 Pfizer Inc. Composição oral líquida com estabilidade melhorada e seu processo para a preparação
WO2016084099A1 (en) * 2014-11-25 2016-06-02 Biological E Limited Soft gelatin capsule composition of anti-tussive agents

Also Published As

Publication number Publication date
CN113795244A (zh) 2021-12-14
TW202100140A (zh) 2021-01-01
MX2021010959A (es) 2021-10-13
WO2020185904A1 (en) 2020-09-17
AR118320A1 (es) 2021-09-29
KR20210137161A (ko) 2021-11-17
CA3134031A1 (en) 2020-09-17
IL286239A (en) 2021-10-31
AU2020235883A1 (en) 2021-11-11
BR112021017876A2 (pt) 2021-12-07
US20220175683A1 (en) 2022-06-09
JP2022526238A (ja) 2022-05-24
EP3937910A1 (en) 2022-01-19

Similar Documents

Publication Publication Date Title
BR112018005349A2 (pt) preparação farmacêutica de anticorpo anti-pd-1 estável e sua aplicação em medicamentos
BR112017008660A2 (pt) formulação de solução de proteína estável contendo alta concentração de um anticorpo anti-vegf
CL2017003209A1 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
ES2556585T3 (es) Composiciones que comprenden sulfato de salbutamol
AR100519A1 (es) Envase tipo cápsula de gelatina blanda y su método de fabricación
CO2017012766A2 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
CO2022007168A2 (es) Cápsulas de gelatina blanda de liberación retardada en ambientes de ph más alto
AR115269A1 (es) Cápsulas de gelatina blanda entéricas
BR112015022946A8 (pt) Forma de dosagem de cápsula de gelatina macia farmacêutica com goma guar modificada
CO2020002628A2 (es) Formulaciones de copanlisib
CO2021001979A2 (es) Formas farmacéuticas orales biodisponibles
AR124043A1 (es) Cápsulas blandas de liberación retardada
PH12016500414B1 (en) Solid preparation containing choline alfoscerate and method for preparing same
CO2021012391A2 (es) Estabilidad api mejorada en capsulas blandas
EA201691034A1 (ru) Композиции в твердой форме с замедленным высвобождением для перорального введения
EA201890477A1 (ru) Инкапсулированная композиция финголимода
CR20200552A (es) Fórmula de suspención de alta concentración para medicamentos en cápsula de gel blanda paae resfriado y gripe
TW202440066A (zh) 於軟凝膠中改善api穩定性
EA202091611A2 (ru) Не содержащая наполнитель фармацевтическая композиция, содержащая фенозановую кислоту
AR102572A1 (es) Formulación de solución de proteína estable que contiene alta concentración de un anticuerpo anti-vegf
ES2555485T1 (es) Composiciones farmacéuticas que contienen un agente activo
AR123805A1 (es) Cápsulas blandas de liberación modificada
EA202091610A3 (ru) Фармацевтические композиции, содержащие фенозановую кислоту
TN2019000197A1 (fr) Liquid filled hard capsule comprising effective and flexible single dose of vitamin D
DOP2019000190A (es) Composición de liberación rápida de cinitaprida y simeticona y proceso para prepararla.